180 related articles for article (PubMed ID: 21515590)
1. The costs of atrial fibrillation in patients with cardiovascular comorbidities--a longitudinal analysis of German health insurance data.
Reinhold T; Lindig C; Willich SN; Brüggenjürgen B
Europace; 2011 Sep; 13(9):1275-80. PubMed ID: 21515590
[TBL] [Abstract][Full Text] [Related]
2. Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
Wu EQ; Birnbaum HG; Mareva M; Tuttle E; Castor AR; Jackman W; Ruskin J
Curr Med Res Opin; 2005 Oct; 21(10):1693-9. PubMed ID: 16238910
[TBL] [Abstract][Full Text] [Related]
3. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
Amin AN; Jhaveri M; Lin J
Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
[TBL] [Abstract][Full Text] [Related]
4. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
5. Cost of atrial fibrillation in United States managed care organizations.
Kim MH; Lin J; Hussein M; Kreilick C; Battleman D
Adv Ther; 2009 Sep; 26(9):847-57. PubMed ID: 19768638
[TBL] [Abstract][Full Text] [Related]
6. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.
Kim MH; Johnston SS; Chu BC; Dalal MR; Schulman KL
Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):313-20. PubMed ID: 21540439
[TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
8. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.
Stock SA; Redaelli M; Wendland G; Civello D; Lauterbach KW
Diabet Med; 2006 Mar; 23(3):299-305. PubMed ID: 16492214
[TBL] [Abstract][Full Text] [Related]
9. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation.
Kim MH; Klingman D; Lin J; Battleman DS
Pharmacotherapy; 2009 Dec; 29(12):1417-26. PubMed ID: 19947801
[TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation.
Ladapo JA; David G; Gunnarsson CL; Hao SC; White SA; March JL; Reynolds MR
J Cardiovasc Electrophysiol; 2012 Jan; 23(1):1-8. PubMed ID: 21777324
[TBL] [Abstract][Full Text] [Related]
11. National assessment of Medicare prescription plan coverage gaps among patients with atrial fibrillation in the US.
Kim MH; Lin J; Kreilick C
Adv Ther; 2009 Aug; 26(8):784-94. PubMed ID: 19690820
[TBL] [Abstract][Full Text] [Related]
12. Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries.
Holstenson E; Ringborg A; Lindgren P; Coste F; Diamand F; Nieuwlaat R; Crijns H
Europace; 2011 Jan; 13(1):23-30. PubMed ID: 20823043
[TBL] [Abstract][Full Text] [Related]
13. [Atrial fibrillation in Germany: A prospective cost of illness study].
Spyra A; Daniel D; Thate-Waschke IM; Berghaus S; Willich S; Zeymer U; Rychlik R
Dtsch Med Wochenschr; 2015 Jul; 140(14):e142-8. PubMed ID: 26182263
[TBL] [Abstract][Full Text] [Related]
14. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
Tscheulin DK; Drevs F
Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and economic burden of pulmonary embolism in Germany.
Kröger K; Küpper-Nybelen J; Moerchel C; Moysidis T; Kienitz C; Schubert I
Vasc Med; 2012 Oct; 17(5):303-9. PubMed ID: 22751745
[TBL] [Abstract][Full Text] [Related]
17. [Patients suffering from atrial fibrillation in Germany. Characteristics, resource consumption and costs].
Reinhold T; Rosenfeld S; Müller-Riemenschneider F; Willich SN; Meinertz T; Kirchhof P; Brüggenjürgen B
Herz; 2012 Aug; 37(5):534-42. PubMed ID: 22301729
[TBL] [Abstract][Full Text] [Related]
18. Comparative cost analysis of outpatient and inpatient rehabilitation for musculoskeletal diseases in Germany.
Zeidler J; Mittendorf T; Vahldiek G; Zeidler H; Merkesdal S
Rheumatology (Oxford); 2008 Oct; 47(10):1527-34. PubMed ID: 18682412
[TBL] [Abstract][Full Text] [Related]
19. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
Wolfenstetter SB
Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance.
Stock SA; Stollenwerk B; Redaelli M; Civello D; Lauterbach KW
J Womens Health (Larchmt); 2008 Apr; 17(3):343-54. PubMed ID: 18338965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
